In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

The Cancer Patient and Cardiology

CRT Workshop - 23 & 24 January 2020, Hotel Nuevo – Madrid, Spain

23/01/2020 14:00 24/01/2020 13:45 Europe/Paris The Cancer Patient and Cardiology

Access event page

contact@escardio.org DD/MM/YYYY
In-person
event

Summary

Chairpersons: Prof. G. Minotti (ESC), Prof. J.-L. Zamorano (ESC), Dr C. Gottfridsson (AstraZeneca)



Objectives of the workshop

Cardio-oncology is the discipline that focuses on mechanisms and clinical manifestations of cardiovascular toxicity induced by cancer therapies.

Oncologists, haematologists, and radiation therapists are constantly faced with the risk of cardiovascular events in cancer patients. Old drugs are increasingly combined with or replaced by newer drugs, and hence cancer patients often present with a blend of toxicities. Furthermore, avalanches of new drugs are running in the pipeline of pharmaceutical companies, which anticipates the emergence of new clinical phenotypes of cardiovascular toxicity in the next few years. This calls for devising optimal but sustainable strategies of patient surveillance and prevention of cardiovascular events.
ESC is committed to promoting knowledge and awareness for all stakeholders in cardio-oncology (doctors, patients, caregivers, drug developers).

The aim of this workshop is to review main cardio-oncology issues from preclinical, clinical, and regulatory issues, thereby fostering cross-fertilization between academic and industrial parties.
New avenues to patient advocacy and research funding opportunities will also be explored

View the Biographies

SESSION 1

CARDIO-ONCOLOGY: A REVIEW AND INTRODUCTION

Moderated by J-L. Zamorano and Dr A. Chan (Pfizer)

13:10 - 13:30

Cardiovascular Effects of Cancer Drugs: Mechanisms and Clinical Trajectories

Prof. Giorgio Minotti, IT

13:30 - 13:50

Radiation Therapy and Cardiovascular Disease       

Prof. J. H. Maduro, NL

SESSION 2

CLINICAL MANAGEMENT OF CANCER PATIENTS

Moderated by Prof. S. Achenbach and Prof. A. Goncalves (Philips)

14:30 - 14:50

Cardiovascular Risk Stratification and Mitigation

Prof. Thomas Suter, CH      

14:50 - 15:10

Early Diagnosis of Subclinical Cardiovascular Toxicity

Dr Daniela Cardinale, IT

15:10 - 15:30

Role of Imaging

Dr Juan Cardlos Plana Gomez, USA

15:30 - 15:50

Hypertension, Atrial Fibrillation and Thrombosis

Dr Riccardo Asteggiano, IT

SESSION 3

PREVENTION AND TREATMENT

Moderated by Prof. G. Minotti and Dr Soergel (Novartis)

17:00 - 17:20

Current Recommendations: the ESC Consensus Document

Prof. Jose Luis Zamorano, ES

17:20 - 17:40

Cardio-Oncology Trials

Dr Torbjørn Omland, NO

17:40 - 18:00

Physical Exercise and Lifestyle: What Do We Know?

Dr Jessica Scott, USA

SESSION 4

CANCER DRUGS AND CV EVENTS IN SPECIAL POPULATIONS

Moderated by Prof. T Suter and Dr Gottfridsson (AstraZeneca)

08:45 - 09:05

Childhood Cancer Treatment and Lifelong Risk of Cardiovascular Events

Dr E.A.M. Feijen, NL

09:05 - 09:25

Cancer and Cardiovascular Risk in the Elderly

Dr Teresa Lopez-Fernandez, ES

09:25 - 09:45

New Immune Therapies and Cardiovascular Side Effects

Dr Javid Moslehi, USA

SESSION 5

AN OUTLOOK

Moderated by Prof. J.L. Zamorano and Dr S. Schroeder (Bayer)

10:30 - 10:50

Cardiovascular Side Effects of Cancer Drugs: Need for Regulatory Issues in Pre-Clinical and Clinical Development

Prof. Giorgio Minotti, IT

10:50 - 11:10

How the EU Framework Programme for Research Can Support Research on Interaction between Cancer and CVD

Dr G. Owsianik, EU Commission

11:10 - 11:30

How ECPC and ESC Could Join Forces as Advocates

Ms Antonella Cardone, ECPC, European Cancer Patient Coalition

11:30 - 11:50

What Can ESC Advocacy Do?

Prof. Lina Badimon, ES